Bell Katharina, Beutgen Vanessa M, Nickels Stefan, Lorenz Katrin, Scheller Yvonne, Elbaz Hisham, Peto Tunde, Ponto Katharina A, Schulz Andreas, Wild Philipp S, Münzel Thomas, Lackner Karl J, Schmidtmann Irene, Beutel Manfred, Pfeiffer Norbert, Grus Franz H, Schuster Alexander K
Department of Ophthalmology, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany.
Department of Ophthalmology, Otto-Von-Guericke University, Magdeburg, Germany.
J Ophthalmol. 2020 Jul 29;2020:8386160. doi: 10.1155/2020/8386160. eCollection 2020.
Retinal vein occlusion (RVO) is the second most common retinal vascular disease and a major cause of visual impairment. In this study, we aimed to observe whether RVO cases have different antibody profiles as a new potential risk factor and whether a conversion of retinal vein occlusion (RVO) to neovascular glaucoma (NVG), one of the major complications, is occurring within a 5-year timeframe.
We performed a nested case-control study (1 : 4) within the Gutenberg Health Study (GHS), a population-based, prospective cohort study in the Rhine-Main Region of Germany including 15,010 participants. RVO subjects ( = 59) were identified by grading of fundus photographs. Optic nerves of RVO subjects and age- and sex-matched controls ( = 229) at baseline and their follow-up examination after 5 years were analyzed for glaucomatous alterations. Of all RVO subjects and controls, serum autoantibody profiles were measured using in-house manufactured antigen-antibody microarrays.
Of the 59 RVO patients, 3 patients (5%) showed glaucomatous optic disc alterations at baseline, whereas no new glaucoma case was detected at 5-year follow-up. Four of the autoantibodies measured (against dermcidin, neurotrophin-3, superoxide dismutase 1, and signal recognition particle 14 kDa protein) were significantly increased in the serum of RVO patients ( < 0.001). Multivariable conditional logistic regression analysis showed that 3 of these 4 antibodies were independent of cardiovascular risk factors.
We found several autoantibodies associated with RVO, targeting proteins and structures possibly involved in RVO pathogenesis.
视网膜静脉阻塞（RVO）是第二常见的视网膜血管疾病，也是视力损害的主要原因。在本研究中，我们旨在观察RVO病例是否具有不同的抗体谱作为一种新的潜在风险因素，以及视网膜静脉阻塞（RVO）是否会在5年时间内转变为主要并发症之一的新生血管性青光眼（NVG）。
我们在古登堡健康研究（GHS）中进行了一项巢式病例对照研究（1∶4），GHS是一项基于人群的前瞻性队列研究，位于德国莱茵-美因地区，包括了15010名参与者。通过眼底照片分级确定RVO受试者（n = 59）。对RVO受试者以及年龄和性别匹配的对照组（n = 229）在基线时的视神经以及5年后的随访检查进行青光眼性改变分析。对所有RVO受试者和对照组，使用自制的抗原-抗体微阵列测量血清自身抗体谱。
在59例RVO患者中，3例患者（5%）在基线时出现青光眼性视盘改变，而在5年随访中未检测到新的青光眼病例。所检测的四种自身抗体（抗皮肤杀菌肽、神经营养因子-3、超氧化物歧化酶1和信号识别颗粒14 kDa蛋白）在RVO患者血清中显著升高（P < 0.001）。多变量条件逻辑回归分析表明，这4种抗体中的3种与心血管危险因素无关。
我们发现了几种与RVO相关的自身抗体，其靶向可能参与RVO发病机制的蛋白质和结构。
